Carcinoma, Non-Small-Cell Lung Clinical Trial
— OPERAGEOfficial title:
Comprehensive Geriatric Assessment and Complications Following Lung Resection for Lung Cancer - A Prospective Observational Study in Elderly Patients With Non-small Cells Lung Cancer
schema : Prospective prognostic study The main objective is to study the value of the Comprehensive Geriatric Assessment in predicting the risk of post operative complications after lung resection for cancer.
Status | Completed |
Enrollment | 302 |
Est. completion date | June 2013 |
Est. primary completion date | June 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 70 Years and older |
Eligibility |
Inclusion Criteria: - Patient 70 years and more - Lung tumour of clinical staging I to IIIB receiving curative lung resection Exclusion Criteria: - Diagnosis of non small lung cancer invalidated by the histological findings of the operative sample - psychological conditions, social support or geographical conditions not allowing the study follow up - Pre operative chemotherapy or radiotherapy |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
France | Site 12 | Aix En Provence | |
France | Centre Hospitalier Universitaire | Angers | |
France | Centre Hospitalier D Argenteuil | Argenteuil | Val D'oise |
France | Centre Hospitalier du Morvan | Brest | |
France | Centre François Baclesse | Caen | |
France | Centre Hospitalier René Dubos | Cergy-pontoise | |
France | Site 30 | Charleville Mezieres | |
France | Site 33 | Creteil | |
France | Site 07 | Draguignan | |
France | Site 32 | Elbeuf | |
France | Site 04 | GAP | |
France | Centre Hospitalier Les Oudairies | La Roche Sur Yon | |
France | Site 41 | Le Chesnay | |
France | Hospital du Cluzeau | Limoges | |
France | Centre Hospitalier Régional | Longjumeau | |
France | Site 06 | Marseille | |
France | Site 42 | Orleans | |
France | Hospital Saint Antoine | Paris | |
France | Site 19 | Perigueux | |
France | Site 20 | Rennes | |
France | Site 17 | Rouen | |
France | Site 18 | Rouen | |
France | Hôpital Yves Le Foll | Saint Brieuc | |
France | Site 14 | Toulon | |
France | Site 11 | Villefranche Sur Saone |
Lead Sponsor | Collaborator |
---|---|
Groupe Francais De Pneumo-Cancerologie |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Post operative morbidity à 30-day | Post operative morbidity at 30-day : Post operative complications occurred during 30 days post surgery, evaluated with CTCAE V3.0. Complications grade 2.3.4 will be analyzed from day 1 up to day 30, collected at Day 1,Day 10, Day 30. A data collection is scheduled at Day 90 for delayed complications. Evaluation : preoperative at Day-30 up to Day 0, Postoperative at Day 10, day 30, Day 90, Day 360. |
March 2014 | No |
Secondary | Post operative mortality | Post operative mortality : mortality from Day 1 to Day 30 and survival at Day 360. Quality of life will be evaluated by : LCSS Spitzer index ADL,IADL. |
March 2014 | No |
Secondary | Length of post operative hospital stay | Length of post operative hospital stay : hospitalization duration : intensive care, surgery department evaluated at Day 10 and post operative visit Day 30. | March 2014 | No |
Secondary | Length of intensive care unit stay | Length of intensive care unit stay evaluated at Day 10 (hospital release)and post operative visit at Day 30 | March 2014 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04879849 -
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
|
Phase 1 | |
Completed |
NCT04426825 -
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT02810457 -
Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02864394 -
Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)
|
Phase 3 | |
Recruiting |
NCT04592523 -
A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea
|
||
Recruiting |
NCT04838548 -
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT04077463 -
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05167604 -
Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
|
||
Recruiting |
NCT04603807 -
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
|
Phase 3 | |
Completed |
NCT04948411 -
Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil
|
||
Active, not recruiting |
NCT04487080 -
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Not yet recruiting |
NCT04255836 -
Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
Completed |
NCT01953913 -
Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
|
Phase 3 | |
Recruiting |
NCT05715229 -
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
|
Phase 2 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Suspended |
NCT05421936 -
Osimertinib for NSCLC With Uncommon EGFR Mutations
|
||
Completed |
NCT02847377 -
A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC
|
N/A | |
Completed |
NCT04427072 -
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
|
Phase 3 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A |